Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.13
Nov 19 • 3:59 PM ET Dollar change+0.03 Percentage change(1.43%)
Aftermarket Close
2.11
Aftermarket • 7:30 PM ET Dollar change-0.02 Percentage change(-0.94%)
Index
-
Market Cap
216.77M
Enterprise Value
132.92M
Income
-45.27M
Sales
24.97M
Book/sh
0.48
Cash/sh
0.87
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
122
IPO
Sep 23, 2016
P/E
-
Forward P/E
6.58
PEG
-
P/S
8.68
P/B
4.45
P/C
2.45
P/FCF
-
EV/EBITDA
-
EV/Sales
5.32
Quick Ratio
0.93
Current Ratio
0.85
Debt/Eq
0.14
LT Debt/Eq
0.11
Option/Short
Yes / Yes
EPS (ttm)
-0.52
EPS next Y
0.32
EPS next Q
-0.17
EPS this Y
43.67%
EPS next Y
169.31%
EPS next 5Y
-
EPS past 3/5Y
1.71% 1.71%
Sales past 3/5Y
1.45% -23.52%
EPS Y/Y TTM
38.30%
Sales Y/Y TTM
384.77%
EPS Q/Q
18.53%
Sales Q/Q
240.35%
Insider Own
38.53%
Insider Trans
0.00%
Inst Own
23.92%
Inst Trans
-1.46%
ROA
-23.68%
ROE
-81.75%
ROIC
-126.02%
Gross Margin
-
Oper. Margin
-192.61%
Profit Margin
-181.34%
SMA20
-4.08%
SMA50
-12.75%
SMA200
-19.28%
Trades
Shs Outstand
101.77M
Shs Float
62.56M
52W High
3.90 -45.38%
52W Low
2.02 5.71%
Volatility
5.18% 7.33%
ATR (14)
0.15
RSI (14)
42.65
Beta
1.61
Rel Volume
3.08
Avg Volume
196.75K
Volume
605,430
Perf Week
-0.47%
Perf Month
-13.77%
Perf Quarter
-26.55%
Perf Half Y
-25.26%
Perf YTD
-32.17%
Perf Year
-31.73%
Perf 3Y
-31.07%
Perf 5Y
-61.06%
Perf 10Y
-86.08%
Prev Close
2.10
Price
2.13
Change %
1.43%
Consensus
Strong Buy
Avg. Price Target
$8.40
Implied Upside
+294.4%
Analysts6incl. previous ratings
Rating Distribution4 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 31, 2024Initiated
BBTIG Research
Buy$8+275.6%
Feb 01, 2019Downgrade
UBS logoUUBS
Buy → Neutral
Jan 04, 2019Initiated
UBS logoUUBS
Buy
Apr 05, 2018Initiated
HH.C. Wainwright
Buy$18+745.1%
Mar 23, 2018Downgrade
CCredit Suisse
Outperform → Neutral
Oct 18, 2016Initiated
LLeerink Partners
Outperform
Oct 18, 2016Initiated
JEF logoJJefferies
Buy$25+1,073.7%
Oct 18, 2016Initiated
CCredit Suisse
Outperform$18+745.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pfeifer AndreaChief Executive OfficerMay 15 '26Sale2.7910,00027,9353,820,288May 18 04:25 PM
ANDREA M.A PFEIFERDirectorMay 15 '26Proposed Sale2.8020,00056,000May 15 04:26 PM
ANDREA M.A PFEIFEROfficerApr 15 '26Proposed Sale3.1910,00031,900Apr 15 04:52 PM
ANDREA M.A PFEIFEROfficerJan 15 '26Proposed Sale3.6730,000110,100Jan 15 04:25 PM
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.
CFO & VP of FinanceMr. Christopher Roberts
Chief Operating OfficerMr. Piergiorgio Donati
Ph.D.Dr. Martin Zugel M.D.
Senior VP of Investor Relations & Corporate CommunicationsDr. Gary Anthony Waanders Ph.D.
Senior VP & General CounselDr. Matthias Maurer Ph.D.